IDEXX Laboratories, Inc. vs Transocean Ltd — how do they compare? IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B), while Transocean Ltd trades at $5.57 (market cap $6.19B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.5× Transocean Ltd's market cap, and Transocean Ltd is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Transocean Ltd for 18 Days on average.
| IDXX | RIG | |
|---|---|---|
Market Cap | $40.43B | $6.19B |
Volume | 692,164 | 30,564,415 |
Sector | Health | Energy |
52-Week High | $766.68 | $7.58 |
52-Week Low | $504.70 | $3.08 |
Typical Hold Time | 46 Days | 18 Days |
Enterprise Value | $41.32B | $10.80B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
Transocean (RIG) trades at $5.39, down slightly by 0.19%, with a bearish technical signal from moving averages. The company reported a net loss of $2.92 billion in 2025, though revenue remains stable near $4 billion. Recent news highlights the $5.8 billion Valaris acquisition, approved by the DOJ, and new contracts like the $80 million deal for the Deepwater Conqueror, providing operational momentum amid a challenging profitability landscape.
The outlook is speculative, hinging on successful deleveraging and integration of the Valaris deal to improve cash flow. Key risks include high debt levels, execution challenges, and persistent negative margins. Analyst sentiment is mixed, with a 39% buy rating, reflecting cautious optimism tied to offshore cycle strength and debt reduction progress.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →